Supporting Development and Commercialization Strategy with Burden of Illness Data

photo illustration of person with medical icons

Multinational Observational Study in Chronic Idiopathic Urticaria


This work yielded key data on the HRQOL and financial burden experienced by patients affected by CIU. The results demonstrated that CIU has significant impact on patients’ lives and that patients with more severe symptoms experienced greater HRQOL impairment.

Ultimately, the client now had reliable real-world evidence to support the value proposition for treatment of CIU. Additionally, they had critical HRQOL and cost data to inform their development and commercialization plans.


Our client wanted to measure real-world treatment patterns, healthcare resource use, HRQOL, and indirect burden associated with chronic idiopathic urticaria (CIU). They needed this data to understand the natural history of the disease and inform clinical development and commercial strategy for their product.


  • We conducted an observational, noninterventional, multinational, multicenter study that included a patient chart abstraction and a cross-sectional patient survey
  • The patient survey used a prospective 7-day patient diary to evaluate HRQOL and productivity
  • Patients represented 7 countries and included 100 patients per country